AstraZeneca's Q1 print confirmed ↗ that eleglipron, the company's oral small-molecule GLP-1 receptor agonist, met primary endpoints in two Phase 2b trials: VISTA in obesity (NCT06579092, 310 patients, 26-week weight loss) and SOLSTICE in type 2 diabetes (NCT06579105, 406 patients, 26-week HbA1c versus semaglutide ↗ and placebo). The company held back exact weight-loss numbers, framing the molecule as "very competitive," with full data scheduled for the American Diabetes Association meeting in June. Eleglipron's success cements a comprehensive Phase 3 obesity-and-T2D program and adds AstraZeneca to the oral GLP-1 race that had been a Lilly-Novo duopoly.
The licensing context. Eleglipron (formerly elecoglipron / AZD5004 / ECC5004) was licensed by AstraZeneca from Eccogene in late 2023 in a deal that included $185 million upfront and substantial milestones. The molecule had completed Phase 1 with encouraging weight-loss data; the Phase 2b VISTA and SOLSTICE trials were the proof-of-concept readouts AstraZeneca needed before committing to a full Phase 3 program. With both endpoints met and ADA data scheduled, the company has now confirmed the comprehensive Phase 3 commitment.
The Phase 2b designs. VISTA enrolled 310 obesity patients (BMI ≥30 or ≥27 with comorbidities), randomized to eleglipron or placebo for 26 weeks, with weight-loss as the primary endpoint. SOLSTICE enrolled 406 type 2 diabetes patients, randomized 1:1:1 to eleglipron, semaglutide (active comparator), or placebo for 26 weeks, with HbA1c change as primary. The active-comparator arm in SOLSTICE is the more important design choice. A clean win against semaglutide on HbA1c at 26 weeks would be commercially significant; a non-inferiority result would also be publishable but commercially weaker. AstraZeneca's "very competitive" framing leaves both readings open, and the ADA disclosure will determine which one the data support.
The competitive context. The oral GLP-1 obesity market currently has two products in active launch: Novo's Wegovy ↗ pill (oral semaglutide) and Lilly's Foundayo (orforglipron). Novo's Wegovy pill posted 1.3M Q1 prescriptions ↗; Foundayo posted 5,612 weekly scripts at Week 3. Eleglipron is the third oral GLP-1 in serious late-stage development, and AstraZeneca brings substantially deeper commercial infrastructure than the typical biotech entrant. If eleglipron's Phase 3 reads positively and the molecule reaches FDA approval in 2027-2028, the oral GLP-1 market becomes a three-way commercial competition rather than the two-horse race the section has been tracking.
The pipeline behind eleglipron. AstraZeneca's broader obesity strategy includes the SYH2082 dual-agonist (GLP-1/GIP, from CSPC Pharmaceuticals via the $18.5B 2025 collaboration) and the LiquidGel monthly-dosing platform that the company is using as a delivery technology for additional candidates. Eleglipron is the lead asset; the dual-agonist and the LiquidGel platform extend the strategy into multi-receptor and longer-dosing-interval territory respectively. The full Phase 3 program will include monotherapy and fixed-dose combination studies.
What ADA reveals. The June ADA meeting in Chicago is the venue for full eleglipron Phase 2b data. Three numbers will determine the commercial trajectory. First, the absolute weight loss in VISTA (anything substantially below the 14-15% range standard semaglutide pivotal data shows would be a competitive disappointment). Second, the active-comparator delta in SOLSTICE (eleglipron vs semaglutide on HbA1c, where a positive non-inferiority is the floor and a superiority finding is the ceiling). Third, the GI tolerability profile (the eleglipron Phase 1 hint was that the small-molecule structure produces less GI burden than peptide GLP-1s, which would be a meaningful differentiator if it holds at scale).
The platform read. The GLP-1R ↗ target page on peptidemodel anchors the section's metabolic-drug coverage. Eleglipron is small-molecule, like Foundayo, and sits outside the platform's peptide focus. The pattern of small-molecule entrants gaining commercial ground against peptide-only competitors continues to widen the peptide-vs-small-molecule split that the section has tracked across the Foundayo launch ↗ and earlier coverage. Whether the small-molecule oral entrants converge on the peptide oral entrants on weight-loss efficacy or remain a tier below is the central commercial question for the category.
What 2027 has to answer. Whether AZ's Phase 3 program executes on schedule. Whether the SOLSTICE active-comparator data show eleglipron at parity with or above semaglutide on HbA1c. And whether AstraZeneca's commercial infrastructure converts the molecule into a viable commercial product against the established Novo and Lilly franchises. Each question is testable within 24 months of the planned Phase 3 starts.